Taro Pharma (TARO) Tops Q3 EPS by 5c

Taro Pharma (NYSE: TARO) reported Q3 EPS of $0.23, $0.05 better than the analyst estimate of $0.18. Revenue for the quarter came in at $148.2 million versus the consensus estimate of $161.14 million.

For earnings history and earnings-related data on Taro Pharma (TARO) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Robinhood shares climb on summit momentum and analyst support
• RBC cuts Northrop Grumman rating on slower growth, cautious defense outlook